利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.033 秒)

    Microimplants for ocular administration
    5.
    发明申请
    Microimplants for ocular administration 审中-公开
    用于眼部给药的微量植入物

    公开(公告)号：US20060204548A1

    公开(公告)日：2006-09-14

    申请号：US11070158

    申请日：2005-03-01

    申请人： Thierry Nivaggioli ,  David Weber

    发明人： Thierry Nivaggioli ,  David Weber

    IPC分类号： A61F2/00 ,  A61K31/56 ,  A01N45/00

    CPC分类号： A61F9/0017 ,  A61F2210/0004 ,  A61K9/0051 ,  A61K9/204

    摘要： Implants and microimplants are provided comprising homogeneous mixtures of active ingredient and bioerodible polymer, including microimplants having diameters of 0.019 inches or less and which can be delivered to the eye using self-sealing methods. Methods of manufacturing the implants and microimplants are provided that yield batches of highly uniform implants and microimplants within very narrow tolerance ranges.

    摘要翻译： 提供植入物和微量植入物，其包括活性成分和生物可腐蚀聚合物的均匀混合物，包括直径为0.019英寸或更小的微量植入物，并且可以使用自密封方法将其递送至眼睛。 提供了制造植入物和微量植入物的方法，其在非常窄的公差范围内产生高度均匀的植入物和微量植入物的批次。

    Liquid formulations for treatment of diseases or conditions
    6.
    发明申请
    Liquid formulations for treatment of diseases or conditions 审中-公开

    公开(公告)号：US20060258698A1

    公开(公告)日：2006-11-16

    申请号：US11351761

    申请日：2006-02-09

    申请人： Sreenivasu Mudumba ,  Philippe Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    发明人： Sreenivasu Mudumba ,  Philippe Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    IPC分类号： A61K31/4745

    CPC分类号： A61K9/0046 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/045 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

    Drug delivery systems for treatment of diseases or conditions
    7.
    发明申请
    Drug delivery systems for treatment of diseases or conditions 审中-公开
    用于治疗疾病或病症的药物输送系统

    公开(公告)号：US20060257450A1

    公开(公告)日：2006-11-16

    申请号：US11386290

    申请日：2006-03-21

    申请人： Sreenivasu Mudumba ,  Philippe Jm Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    发明人： Sreenivasu Mudumba ,  Philippe Jm Dor ,  Thierry Nivaggioli ,  David Weber ,  Sidiq Farooq

    IPC分类号： A61K31/4745 ,  A61F2/02

    CPC分类号： A61K9/0051 ,  A61K31/436 ,  A61K31/4745

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是用于向这些组织提供治疗剂的延长递送的固体药物递送系统和方法。 固体药物递送系统可以放置在受试者中，包括但不限于在巩膜和结膜之间的放置或经巩膜​​放置。 描述的方法可用于施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成，年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 固体药物递送装置可以包含雷帕霉素或其它治疗剂。 还描述了通过在近视眼装置上施用抗增生剂（包括但不限于雷帕霉素）来治疗眼部疾病或病症的方法。

    Formulations for ocular treatment
    8.
    发明申请
    Formulations for ocular treatment 审中-公开
    眼部治疗剂型

    公开(公告)号：US20060182771A1

    公开(公告)日：2006-08-17

    申请号：US11351844

    申请日：2006-02-09

    申请人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    发明人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    IPC分类号： A61K31/4745 ,  A61K9/00

    CPC分类号： A61K9/0046 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/045 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.

    摘要翻译： 可以通过向这些组织施用治疗剂来有效地治疗与身体组织（包括眼睛中的组织）相关的疾病和病症。 本文描述了将治疗剂递送到这种组织的自乳化制剂和方法。 自乳化制剂可以递送到受试者的水性介质，包括但不限于玻璃体。 例如，可以使用方法来施用雷帕霉素或相关化合物以治疗或预防与年龄相关性黄斑变性相关的脉络膜新血管形成，或治疗干性AMD。 自乳化制剂也可以全身施用，例如口服给药以治疗受试者的移植排斥。 自乳化制剂可以包含雷帕霉素，相关化合物或其它治疗剂。

    System for generation of useful electrical power from isotopic emissions
    10.
    发明授权
    System for generation of useful electrical power from isotopic emissions 有权

    公开(公告)号：US10109384B2

    公开(公告)日：2018-10-23

    申请号：US13961125

    申请日：2013-08-07

    申请人： David Weber

    发明人： David Weber

    IPC分类号： H02N11/00 ,  G21H1/00 ,  G21H1/04 ,  H01J23/05

    摘要： Particles emitted by radio-isotopic by-products of nuclear fission are used as a power source at the cathode of a magnetron system. Particles include high energy electrons having a large associated EMF. In the system a radial electrical vector E, between the cathode and anode, interacts with an axial magnetic vector B vector to produce an E×B force that rotates the particles about the system axis. These emissions are within a set range of velocities. The angular velocity and geometry of a rotating field, known as a space charge wheel (SCW), may be modulated by an external RF inputs to cavities of an anode block and the use of concentric biasing grids between the cathode and anode block. The SCW induces LC values into cavities of the anode, exciting them and producing electrons resonance which may be used to generate power.